Oppenheimer analyst Jay Olson lowered the price target on Nektar Therapeutics (NASDAQ: NKTR) to $5.00 (from $6.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE